bo-0742 and Breast-Neoplasms

bo-0742 has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for bo-0742 and Breast-Neoplasms

Article	Year
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18 A series of 9-anilinoacridine N-mustard derivatives, in which the alkylating N-mustard residue was linked to the C-3' or C-4' position of the anilino ring with an O-ethylene spacer, was synthesized and evaluated for cytotoxicity against human lymphoblastic leukemic cells (CCRF-CEM) in culture. The results showed that all of the new compounds exhibited potent cytotoxicity with IC(50) values ranging from 0.002 to 0.7 microM, which were as potent or significantly more potent than 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA). Compound 9 did not exhibit cross-resistance against both vinblastine-resistant (CCRF-CEM/VBL) and taxol-resistant (CCRF-CEM/taxol) cells. Additionally, compound 9 demonstrated potent antitumor effect in nude mice bearing human breast carcinoma MX-1 xenografts, resulting in complete tumor remission in two out of three mice at the maximal dose of 1-2mg/kg (Q3Dx7) or 3mg/kg (Q4Dx5) via intravenous injection. Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Mice; Mice, Nude; Nitrogen Mustard Compounds; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays	2004

Article

Year

Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.

Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18

A series of 9-anilinoacridine N-mustard derivatives, in which the alkylating N-mustard residue was linked to the C-3' or C-4' position of the anilino ring with an O-ethylene spacer, was synthesized and evaluated for cytotoxicity against human lymphoblastic leukemic cells (CCRF-CEM) in culture. The results showed that all of the new compounds exhibited potent cytotoxicity with IC(50) values ranging from 0.002 to 0.7 microM, which were as potent or significantly more potent than 3-(9-acridinylamino)-5-hydroxymethylaniline (AHMA). Compound 9 did not exhibit cross-resistance against both vinblastine-resistant (CCRF-CEM/VBL) and taxol-resistant (CCRF-CEM/taxol) cells. Additionally, compound 9 demonstrated potent antitumor effect in nude mice bearing human breast carcinoma MX-1 xenografts, resulting in complete tumor remission in two out of three mice at the maximal dose of 1-2mg/kg (Q3Dx7) or 3mg/kg (Q4Dx5) via intravenous injection.

Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Mice; Mice, Nude; Nitrogen Mustard Compounds; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays

2004